Unlimit Group Raises DKK 4 million through a Directed Share Issue to Scale and Grow

Unlimit Group has successfully completed a DKK 4 million ($570,000) direct listing to accelerate scaling and growth. The new capital will strengthen the company's operations and enable it to accelerate the implementation of its pilot projects, marking a significant step in its growth journey. The direct listing is a testament to investors' confidence in the company's strategy and business model.

AstraZeneca (NASDAQ:AZN) has announced a significant shift in its listing structure, aiming to attract a broader range of global investors. The pharmaceutical giant will transition to a direct listing on the New York Stock Exchange, replacing its current depositary receipt structure. This move is part of AstraZeneca's strategy to support its long-term growth while maintaining its headquarters and listing in London AstraZeneca to Adopt Direct U.S. Listing While Retaining London Base^[1].

The decision comes amidst growing concerns among UK investors about the shrinking London market, as companies seek larger valuations abroad. AstraZeneca's transition is part of a broader trend seen in other firms, such as Glencore, Petershill Partners, and Ashtead, which have also considered or moved away from London AstraZeneca to Adopt Direct U.S. Listing While Retaining London Base^[1].

The company's chair, Michel Demare, stated that the new listing structure will enable AstraZeneca to reach a broader mix of global investors, supporting its long-term strategy for sustainable growth. This move follows AstraZeneca's recent pause on a £200 million ($268.8 million) investment in its Cambridge research facility, joining other drugmakers scaling back in the UK due to a challenging business environment AstraZeneca to Adopt Direct U.S. Listing While Retaining London Base^[1].

Additionally, AstraZeneca has pledged to invest $50 billion in U.S. manufacturing by 2030 and lower certain direct-to-patient U.S. drug prices, helping to mitigate potential import tariffs. These measures are part of the company's efforts to align with President Donald Trump's administration's policies AstraZeneca to Adopt Direct U.S. Listing While Retaining London Base^[1].

AstraZeneca's stock price has risen about 5% year-to-date, and the company plans to submit the listing proposal to a shareholder vote on November 3. This direct listing is expected to provide AstraZeneca with the necessary capital to strengthen its operations and accelerate the implementation of its pilot projects.